Medically reviewed by Archana Sharma, DO NSCLC starts in the lungs, but when it metastasizes, it spreads to other body ...

The trial is studying ateganosine followed by cemiplimab in NSCLC patients resistant to checkpoint inhibitors and ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to ...

If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...

Risk of non-small cell lung cancer (NSCLC), a malignancy that develops in the tissues of the lung, increases considerably with smoke exposure.  Doctor | Cancer ...

Adhering to the current guideline standard for intraoperative nodal assessment in resected non–small cell lung cancer (NSCLC) ...

If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...

The FDA has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo) for certain patients with locally-advanced or metastatic epidermal growth factor receptor ...

The discussion transitions to biomarker testing as an essential component of lung cancer diagnosis, with Dr. Florez ...

Tolododekin alfa (ANK-101) is a novel anchored immunotherapy that links interleukin-12 (IL-12) to aluminum hydroxide via an ...

New research presented at the ASCO Annual Meeting 2026 demonstrates that biomarker-guided lung cancer treatment offers ...